James Webb Space Telescope discovers its first exoplanet as stunning image is revealed
This discovery is out of this world.
For the first time since its operations began in 2021, the James Webb Space Telescope (JWST) has captured a direct image, published by the journal Nature, of a new exoplanet — a planet that orbits outside the solar system.
This discovery marks a major breakthrough in astronomy and a 'new step' in the ongoing search for planets that exist beyond our solar system.
This discovery was made possible by a team from France's National Centre for Scientific Research (CNRS), working at the Observatoire de Paris-PSL in partnership with Université Grenoble Alpes.
From Earth, these planets appear directly next to bright stars, so their faint signals often get lost in the glare.
To combat this, the CNRS team designed a chronograph — a special telegraphic tool for the JWST that blocks out a star's light, much like how the Moon blocks out the Sun during a solar eclipse.
Named TWA 7b, the newly discovered planet is surrounded by a swirling disk of rocky debris and dust — remnants from the early stages of planet formation.
It orbits a young star, TWA 7, which has three distinct rings, one of which is especially narrow, and is surrounded by two empty areas. The JWST revealed a source within the heart of this narrow ring.
This exoplanet is 10 times smaller — roughly the size of Saturn — than any exoplanet previously observed using this method.
Which has to be tiny considering the JWST gave way to six distant 'rogue' worlds, discovered by a team at Johns Hopkins University last summer.
At the time, researchers believed that these worlds were potentially brown dwarfs — the astronomical term for failed stars.
'If you have an object that looks like a young Jupiter, is it possible that it could have become a star under the right conditions?' said lead study author Adam Langeveld.
Other relevant discoveries made by the JWST around the same time provided data to researchers from the University of Michigan and Montreal to assume that there are potential oceans and air sources on the exoplanet dubbed LHS 1140 b, which is located within the constellation Cetus in the night sky.
Most exoplanets we know about have been detected using indirect methods like measuring a star's wobble or dimming as a planet crosses in front of it — the method scientists artificially recreated to discover TWA 7 b.
In the bigger picture, learning how planets like TWA 7 b form and shape their surroundings brings us one step closer to understanding the origins of planetary systems, including our own.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Upstream phase of LUMEVOQ® manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions PARIS, June 26, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company's gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc. "This outstanding result is a significant milestone in GenSight's strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory submissions," commented Scott Jeffers, Chief Technical Officer of GenSight Biologics. "Our new partnership is proving to be highly effective, not just in completing the tech transfer process successfully, but also in improving the yield and upgrading the analytical methods used to reinforce control over the safety and quality of each batch. The level of collaboration and coordination between our teams has been truly impressive." Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. It is the only CDMO with a successfully commercialized gene therapy produced in their facility. Catalent offers gene therapy companies both production and in-house testing capabilities, and the GMP capacity at the facility used for LUMEVOQ® will provide GenSight Biologics greater flexibility in the manufacture of the gene therapy. Catalent successfully manufactured the drug product batch that was released as safe for human use in November 2024 and which will be the source of product supply for the named patient early access program (AAC) and dose-ranging study in France. After the tech transfer is completed, Catalent will also manufacture the drug for the planned global Phase III trial RECOVER and the regulatory submissions. The Partnership as a Critical Element of GenSight Biologics' Strategy Following agreement with the French agency ANSM to consider opening the AAC program expeditiously after approval of a dose-ranging study, the Company is currently implementing a financing strategy, as it continues to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner (Catalent) to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom "Our partnership with a manufacturing powerhouse like Catalent is a critical enabler of our global strategy," explained Laurence Rodriguez, CEO of GenSight Biologics. "The outputs from their work with our team will allow us to reassure regulators that we have surmounted the challenges we faced in the past and, ultimately, to fulfill our mission to provide LHON patients a safe and effective treatment for their urgent unmet need." About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. About Leber Hereditary Optic Neuropathy (LHON) Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. About LUMEVOQ® (GS010; lenadogene nolparvovec) LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. "LUMEVOQ" was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® (GS010; lenadogene nolparvovec) has not been registered in any country at this stage. View source version on Contacts GenSight Biologics Chief Financial OfficerJan Eryk Umiastowskijeumiastowski@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
For first time, Webb telescope discovers an alien planet
By Will Dunham WASHINGTON (Reuters) -In addition to providing a trove of information about the early universe, the James Webb Space Telescope since its 2021 launch has obtained valuable data on various already-known planets beyond our solar system, called exoplanets. Now, for the first time, Webb has discovered an exoplanet not previously known. Webb has directly imaged a young gas giant planet roughly the size of Saturn, our solar system's second-largest planet, orbiting a star smaller than the sun located about 110 light-years from Earth in the constellation Antlia, researchers said. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km). Most of the roughly 5,900 exoplanets discovered since the 1990s have been detected using indirect methods, such as through observation of the slight dimming of a star's light when a planet passes in front of it, called the transit method. Less than 2% of them have been directly imaged, as Webb did with the newly identified planet. While this planet is large when considered in the context of our solar system, it is actually the least massive one ever discovered through direct imaging - 10 times less massive than the previous record holder. This speaks to the sensitivity of Webb's instruments. This discovery was achieved using a French-produced coronagraph, a device that blocks out the bright light from a star, installed on Webb's Mid-Infrared Instrument, or MIRI. "Webb opens a new window - in terms of mass and the distance of a planet to the star - of exoplanets that had not been accessible to observations so far. This is important to explore the diversity of exoplanetary systems and understand how they form and evolve," said astronomer Anne-Marie Lagrange of the French research agency CNRS and LIRA/Observatoire de Paris, lead author of the study published on Wednesday in the journal Nature. The planet orbits its host star, called TWA 7, at a distance about 52 times greater than Earth's orbital distance from the sun. To put that in perspective, our solar system's outermost planet Neptune orbits about 30 times further from the sun than Earth. The transit method of discovering exoplanets is particularly useful for spotting those orbiting close to their host star rather than much further out like the newly identified one. "Indirect methods provide incredible information for planets close to their stars. Imaging is needed to robustly detect and characterize planets further away, typically 10 times the Earth- to-sun distance," Lagrange said. The birth of a planetary system begins with a large cloud of gas and dust - called a molecular cloud - that collapses under its own gravity to form a central star. Leftover material spinning around the star in what is called a protoplanetary disk forms planets. The star and the planet in this research are practically newborns - about 6 million years old, compared to the age of the sun and our solar system of roughly 4.5 billion years. Because of the angle at which this planetary system is being observed - essentially looking at it from above rather than from the side - the researchers were able to discern the structure of the remaining disk. It has two broad concentric ring-like structures made up of rocky and dusty material and one narrow ring in which the planet is sitting. The researchers do not yet know the composition of the planet's atmosphere, though future Webb observations may provide an answer. They also are not certain whether the planet, being as young as it is, is still gaining mass by accumulating additional material surrounding it. While this planet is the smallest ever directly imaged, it is still much more massive than rocky planets like Earth that might be good candidates in the search for life beyond our solar system. Even with its tremendous capabilities of observing the cosmos in near-infrared and mid-infrared wavelengths, Webb is still not able to directly image Earth-sized exoplanets. "Looking forward, I do hope the projects of direct imaging of Earth-like planets and searches for possible signs of life will become a reality," Lagrange said.
Yahoo
7 hours ago
- Yahoo
James Webb Space Telescope discovers its first exoplanet as stunning image is revealed
This discovery is out of this world. For the first time since its operations began in 2021, the James Webb Space Telescope (JWST) has captured a direct image, published by the journal Nature, of a new exoplanet — a planet that orbits outside the solar system. This discovery marks a major breakthrough in astronomy and a 'new step' in the ongoing search for planets that exist beyond our solar system. This discovery was made possible by a team from France's National Centre for Scientific Research (CNRS), working at the Observatoire de Paris-PSL in partnership with Université Grenoble Alpes. From Earth, these planets appear directly next to bright stars, so their faint signals often get lost in the glare. To combat this, the CNRS team designed a chronograph — a special telegraphic tool for the JWST that blocks out a star's light, much like how the Moon blocks out the Sun during a solar eclipse. Named TWA 7b, the newly discovered planet is surrounded by a swirling disk of rocky debris and dust — remnants from the early stages of planet formation. It orbits a young star, TWA 7, which has three distinct rings, one of which is especially narrow, and is surrounded by two empty areas. The JWST revealed a source within the heart of this narrow ring. This exoplanet is 10 times smaller — roughly the size of Saturn — than any exoplanet previously observed using this method. Which has to be tiny considering the JWST gave way to six distant 'rogue' worlds, discovered by a team at Johns Hopkins University last summer. At the time, researchers believed that these worlds were potentially brown dwarfs — the astronomical term for failed stars. 'If you have an object that looks like a young Jupiter, is it possible that it could have become a star under the right conditions?' said lead study author Adam Langeveld. Other relevant discoveries made by the JWST around the same time provided data to researchers from the University of Michigan and Montreal to assume that there are potential oceans and air sources on the exoplanet dubbed LHS 1140 b, which is located within the constellation Cetus in the night sky. Most exoplanets we know about have been detected using indirect methods like measuring a star's wobble or dimming as a planet crosses in front of it — the method scientists artificially recreated to discover TWA 7 b. In the bigger picture, learning how planets like TWA 7 b form and shape their surroundings brings us one step closer to understanding the origins of planetary systems, including our own.
